GlucoTrack, Inc. (NASDAQ:GCTK – Get Free Report)’s stock price shot up 9% during mid-day trading on Wednesday . The company traded as high as $0.35 and last traded at $0.3477. 262,735 shares were traded during trading, a decline of 70% from the average session volume of 864,733 shares. The stock had previously closed at $0.3190.
Wall Street Analyst Weigh In
GCTK has been the subject of several recent research reports. Weiss Ratings reiterated a “sell (e+)” rating on shares of GlucoTrack in a research note on Tuesday, April 21st. Wall Street Zen upgraded GlucoTrack to a “sell” rating in a research note on Saturday, May 30th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock has an average rating of “Sell”.
Read Our Latest Analysis on GCTK
GlucoTrack Trading Up 9.0%
Institutional Investors Weigh In On GlucoTrack
A number of institutional investors have recently added to or reduced their stakes in the company. Bank of America Corp DE boosted its position in GlucoTrack by 102,125.0% in the second quarter. Bank of America Corp DE now owns 4,089 shares of the company’s stock worth $25,000 after purchasing an additional 4,085 shares during the last quarter. Boothbay Fund Management LLC bought a new stake in shares of GlucoTrack during the 4th quarter worth $52,000. Finally, Ikarian Capital LLC bought a new stake in shares of GlucoTrack during the 4th quarter worth $177,000. 10.92% of the stock is owned by institutional investors.
About GlucoTrack
GlucoTrack, Inc, a medical device company, focused on the design, development, and commercialization of novel technologies for people with diabetes in the United States. It develops GlucoTrack, a noninvasive glucose monitoring device that helps people with diabetes and pre-diabetics to obtain blood glucose level readings without the pain. The company was formerly known as Integrity Applications, Inc and changed its name to GlucoTrack, Inc in November 2021. GlucoTrack, Inc was founded in 2001 and is based in Rutherford, New Jersey.
See Also
- Five stocks we like better than GlucoTrack
- AirJoule Unveils Prime System, Clearing Path to Commercialization
- Copper Stocks Are Getting a Bigger Spotlight as Gold’s Rally Cracks
- Nike Q4 Beat Masks Core Weakness as Analysts Cut Price Targets
- Uber’s Waymo Detour Tests the Stock’s Robotaxi Bull Case
Receive News & Ratings for GlucoTrack Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlucoTrack and related companies with MarketBeat.com's FREE daily email newsletter.
